Familial colon cancer syndromes: An update of a rapidly evolving field

Current Gastroenterology Reports

Volumn 14, Issue 5, 2012, Pages 428-438

  Patel, Swati G ^a   Ahnen, Dennis J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

EPCAM; Familial adenomatous polypsis; Familial colorectal cancer type X; Hereditary colon cancer; Juvenile polyposis syndrome; Lynch syndrome; MutYH; Peutz Jegher syndrome; PTEN hamartomatous syndrome; Serrated polyposis syndrome

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; EPITHELIAL CELL ADHESION MOLECULE; MISMATCH REPAIR PROTEIN PMS2; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; ROFECOXIB; SULINDAC;

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; COLON RESECTION; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; COWDEN SYNDROME; DISEASE SURVEILLANCE; ENDOMETRIUM CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILIAL COLORECTAL CANCER TYPE X; FAMILY HISTORY; GENE DELETION; GENE MUTATION; HEREDITARY COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE POLYPOSIS SYNDROME; MICROSATELLITE INSTABILITY; MUTYH ASSOCIATED POLYPOSIS; PEUTZ JEGHERS SYNDROME; PREDICTION; PROMOTER REGION; PTEN HAMARTOMATOUS TUMOR SYNDROME; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SERRATED POLYPOSIS SYNDROME; TOTAL COLON RESECTION;

CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; DNA GLYCOSYLASES; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY;

EID: 84870548246     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0280-6     Document Type: Review

References (63)

1. Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366-78.
2. National Cancer Institute. Colon and Rectal Cancer. Retrieved 12/ 29/2011 from http://www.cancer.gov/cancertopics/types/colonand-rectal.
3. Woods MO, Younghusband HB, Parfrey PS, et al. The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease. Gut. 2010;59(10):1369-77. This is a systematic clinical and genetic classification of a large consecutive series of colorectal cancers from the Newfoundland Colorectal Cancer Registry, a region with a high prevalence of familial colorectal cancer.
4. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137(5):1621-7.
5. Bonadona V, Bonaïti B, Olschwang S, et al. French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304-10. This paper describes the colorectal, endometrial, and ovarian cancer risks in a large (537) number of families with Lynch Syndrome and confirms variations in both risk and age of onset by Lynch genotype.
6. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851-60. This older paper is important because it illustrates the low level of recognition of Lynch Syndrome in clinical practice in the United States.
7. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 2009;41:112-7. This is the initial report of EPCAM deletions causing Lynch syndrome due to methylation of MSH2.
8. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn. 2011;13(1):93-9. This collaborative effort reported that of 58 CRCs with MSH2 loss without identifiable mutation, 11 (19%) had EPCAM deletions leading to MSH2 hypermethylation, 1 had MSH2 hypermethylation without EPCAM deletion, and the cause of the others remains to be discovered.
9. Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: A cohort study. Lancet Oncol. 2011;12(1):49-55. This study evaluated cancer prevalence in 194 EPCAM deletion carriers with 16 different deletions and found that endometrial cancer risk was substantially lower in this group than in MMR mutation carriers. In EPCAM deletion carriers, the endometrial cancer risk seemed to be confined to those with deletions that were close to or extended into the MSH2 promoter.
10. Lynch HT, Riegert-Johnson DL, Snyder C, et al. Lynch syndromeassociated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol. 2011;106 (10):1829-36.
11. Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: Do the ends justify the means? Cancer Prev Res (Phila). 2011;4(1):1-5.
12. Jenkins MA, Hayashi S, O'Shea AM, et al. Colon Cancer Family Registry. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: A population-based study. Gastroenterology. 2007;133(1):48-56.
13. Pérez-Carbonell L, Ruiz-Ponte C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012;61(6):865-72.
14. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as firstline screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: A 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33(11):1639-45. Erratum in: Am J Surg Pathol. 2010;34(3):432.
15. Hall G, Clarkson A, Shi A, et al. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology. 2010;42(5):409-13.
16. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM (1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140 (1):73-81. This paper describes and validates a predictive model that adds prediction of MSH6 mutation risk to the previous PREMM 1,2 model.
17. Khan O, Blanco A, Conrad P, et al. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011;106(10):1822-7.
18. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and costeffectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4(1):9-22.
19. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35-41.
20. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: A costeffectiveness analysis. Ann Intern Med. 2011;155(2):69-79. This group developed a Markov model to estimate the relative costeffectiveness of a variety of molecular and clinical predictive models for identification of Lynch syndrome and concluded that universal molecular testing of CRCs with immunohistochemistry (IHC) followed by BRAF mutation analysis of those with MLH1 loss was, overall, the most cost-effective approach, although predictive modeling with MMR Pro followed by IHC was estimated to be almost as effective at less cost.
21. Kwon JS, Scott JL, Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011;29 (16):2247-52.
22. Limburg PJ, Harmsen WS, Chen HH, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol. 2011;9:497-502.
23. Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2010;8(2):174-82.
24. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081-7. This longer term follow-up of a controlled trial of aspirin in Lynch gene carriers raised the possibility of a decrease in CRC risk in those who had been randomized to aspirin. This is the first suggestion of the possibility of effective chemoprevention in this syndrome.
25. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: The advantage of more extensive colon surgery. Gut. 2011;60(7):950-7.
26. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: Familial colorectal cancer type X. JAMA. 2005;293(16):1979-85.
27. Lindor NM. Familial colorectal cancer type X: The other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am. 2009;18(4):637-45. A clearly written review of this recently described clinical syndrome.
28. Klarskov L, Holck S, Bernstein I, et al. Hereditary colorectal cancer diagnostics: Morphological features of familial colorectal cancer type X versus Lynch syndrome. J Clin Pathol. 2012.
29. Koh PK, Kalady M, Skacel M, et al. Familial colorectal cancer type X: Polyp burden and cancer risk stratification via a family history score. ANZ J Surg. 2011;81(7-8):537-42.
30. Francisco I, Albuquerque C, Lage P, et al. Familial colorectal cancer type X syndrome: Two distinct molecular entities? Fam Cancer. 2011;10(4):623-31.
31. Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044-58.
32. Nieuwenhuis MH, Lefevre JH, Bülow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: An international cohort study. Dis Colon Rectum. 2011;54(10):1229-34.
33. Leiden Open Variation Database. InSiGHT (International Society for Gastrointestinal Hereditary Tumours), Leiden University Medical Center, from: Http://chromium.liacs.nl/LOVD2/colon-cancer/. Accessed on January 17, 2012.
34. Newton K, Mallinson E, Bowen J, et al. Genotype-phenotype correlation in colorectalpolyposis. Clin Genet. 2012;81(6):521-31. This paper extends previous genotype/phenotype associations in FAP, showing that patients with mutations near the mutation cluster region have an earlier age of onset of CRC and a poorer survival than those with mutations in other regions of the APC gene.
35. Heinen CD. Genotype to phenotype: Analyzing the effects of inherited mutations in colorectal cancer families. Mutat Res. 2010;693:32-45.
36. Levin B, Lieberman DA, McFarland B, et al. American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-95.
37. Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol. 2011;25:607-22.
38. Burn J, Bishop DT, Chapman PD, et al. International CAPP consortium. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila). 2011;4(5):655-65.
39. Parc Y, Mabrut JY, Shields C, et al. Surgical management of the duodenal manifestations of familial adenomatous polyposis. Br J Surg. 2011;98(4):480-4.
40. Gibbons DC, Sinha A, Phillips RKS, et al. Colorectal cancer: No longer the issue in familial adenomatous polyposis? Fam Cancer. 2011;10:11-20.
41. Terdiman JP. MYH-associated disease: Attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009;137(6):1883-6.
42. Boparai KS, Dekker E, Van Eeden S, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYHassociated polyposis. Gastroenterology. 2008;135(6):2014-8.
43. Cleary SP, Cotterchio M, Jenkins MA, et al. Germline MutY human homologue mutations and colorectal cancer: A multisite case-control study. Gastroenterology. 2009;136(4):1251-60.
44. Nielsen M, van Steenbergen LN, Jones N, et al. Survival of MUTYH-associated polyposis patients with colorectal cancer and matched control colorectal cancer patients. J Nat Cancer Inst. 2010;102(22):1724-30. This paper reported that overall survival of 157 patients with MUTYH-associated CRCs was better than that in matched controls (5 year survival, 78%vs. 63%; HR for death, 0.48).
45. Theodoratou E, Campbell H, Tenesa A, et al. A large-scale metaanalysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer. 2010;103(12):1875-84. This is an extensive meta-analysis that reports a marked increased CRC risk in biallelic MUTYH mutation carriers (OR, 10.9) and a borderline significant increase in mono-allelic mutation carriers (OR, 1.16).
46. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009;137(6):1976-85.
47. Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: A systematic review and recommendations for management. Gut. 2010;59(7):975-86.
48. Bouraoui S, Azouz H, Kechrid H, et al. [Peutz Jeghers' syndrome with malignant development in a hamartomatous polyp: Report of one case and review of the literature] (In French). Gastroenterol Clin Biol. 2008;32:250e4.
49. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz Jeghers syndrome. Clin Cancer Res. 2006;12:3209e15.
50. van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011;60(2):141-7. This report of 133 Dutch PJS patients from 54 families confirms the high overall cancer risk in PJS, as compared with the general population (9-fold), and found a markedly higher cancer risk in women than men (20-fold vs. 5-fold above general population). About half of the cancers occurred in the GI tract.
51. van Lier MG, Mathus-Vliegen EM, et al. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: Time to update surveillance guidelines? Am J Gastroenterol. 2011;106 (5):940-5.
52. You YN, Wolff BG, Boardman LA, et al. Peutz-Jeghers syndrome: A study of long-term surgical morbidity and causes of mortality. Fam Cancer. 2010;9(4):609-16.
53. van Hattem WA, Brosens LA, Marks SY, et al. Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. Clin Gastroenterol Hepatol. 2009;7:93-7.
54. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139(6):1927-33. This paper described the wide spectrum of polyp histologies found in 67 PTEN mutation carriers undergoing colonoscopy, including, in order of frequency, hyperplastic polyps, hamartomatomas, ganglioneuromas, adenomas, and inflammatory polyps.
55. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with Germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-7. This report of cancer risk in 368 PTEN mutation carriers found substantial increases in risk of cancers of the colon and rectum (10-fold), breast (20-fold), thyroid (50-fold), endometrium (40-fold), kidney (30-fold), and melanoma (8-fold).
56. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: An overview. Genet Med. 2009;11(10):687-94.
57. Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet. 2011;88(1):42-56.
58. Boparai KS, Mathus-Vliegen EM, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: A multicentre cohort study. Gut. 2010;59:1094-100. These authors collated the endoscopic and pathologic findings in 77 individuals who met the clinical criteria for serrated polyposis syndrome and found that 35% had CRC (28% at initial colonoscopy) and that an increasing number of serrated polyps were significantly associated with CRC presence.
59. Snover D, Ahnen DJ, Burt RW, et al. Serrated polyps of the colon and rectum and serrated ("hyperplastic") polyposis. In: Bozman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours. Pathology and genetics. Tumours of the digestive system. 4th ed. Berlin: Springer-Verlag; 2010.
60. Orlowska J, Kiedrowski M, Kaminski FM, et al. Hyperplastic polyposis syndrome in asymptomatic patients: The results from the colorectal-cancer screening program. Virchows Arch. 2009;455 Suppl 1:S47.
61. Jass Jr. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113-30.
62. Kalady MF, Jarrar A, Leach B, et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum. 2011;54(2):164-70. This report describes the substantial variability in the phenotypes that occur in individuals who meet the current clinical criteria for serrated polyposis syndrome.
63. Young J, Jass Jr. The case for a genetic predisposition to serrated neoplasia in the colorectum: Hypothesis and review of the literature. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1778-84.